DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for anterior segment dysgenesis 7 — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAnterior segment dysgenesis 7 maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for anterior segment dysgenesis 7 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
patched 1 (PTCH1) — PTCH1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet plmdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6E1H · 3.5 Å · ligand PALMITIC ACID (PLM). Experimental structure, not a prediction.
What the evidence adds up to
In a retrospective Japanese study of 139 patients (220 eyes) with anterior segment dysgenesis and congenital corneal opacities, the most common diagnosis was Peters anomaly (72.7% of eyes), followed by anterior staphyloma (11.4%), Rieger anomaly (7.7%), and sclerocornea (6.4%). Among 61 patients whose visual acuity could be measured, 43.2% had best-corrected visual acuity in the better eye between 20/60 and 20/1000 (low vision), and 24.3% were legally blind (less than 20/1000). Fundus disorders were found in 14.6% of examined eyes, systemic abnormalities in 25.2% of patients, and a family history in only 3.6%. Among 109 patients with Peters anomaly, 46.8% had bilateral disease, 27.5% had a normal fellow eye, and 25.7% had other abnormal findings in the fellow eye.
Two review papers describe anterior segment dysgenesis as a spectrum of disorders caused by abnormal migration and differentiation of neural crest cells, which form the periocular mesenchyme that gives rise to the cornea, trabecular meshwork, and other anterior segment structures. The 2017 review notes that patients with anterior segment dysgenesis are susceptible to infantile glaucoma, congenital endothelial dystrophy, sclerocornea, and aniridia, and that there is overlapping genetic mutation between the anterior segment dysgenesis phenotypic spectrum and primary congenital glaucoma. The 2018 review identifies several genes involved in neural crest cell migration and specification, including PITX2, FOXC1, and Tfap2b.
No drug treatment is mentioned in any of these three papers. The clinical study reports only surgical and observational outcomes, and the reviews focus entirely on embryology and genetics. What is missing is any clinical trial of a pharmacological intervention, any funding for such a trial, and any patient stratification strategy that might identify a subset of anterior segment dysgenesis patients who could respond to a drug. The disease remains defined by developmental anatomy and genetic mutation, not by a druggable pathway with evidence in human patients.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Cornea · 2011 · 57 citations · open access
Clinical Features of Anterior Segment Dysgenesis Associated With Congenital Corneal Opacities
AbstractPURPOSE: Anterior segment dysgenesis is one of the main causes of congenital corneal opacities. In this study, we investigated the clinical features and visual outcomes of patients with anterior segment dysgenesis in a large number of cases. METHODS: The medical records of patients with congenital corneal opacities in relation to anterior segment dysgenesis seen in the National Center for Child Health and Development, Japan, between April 2002 and October 2009, were retrospectively studied. RESULTS: Records of 220 eyes of 139 patients were reviewed. Mean follow-up period was 5 years. Clinical diagnoses were Peters anomaly (72.7%), anterior staphyloma (11.4%), Rieger anomaly (7.7%), sclerocornea (6.4%), and others (1.8%). Visual acuity was measured in 61 patients. The best-corrected visual acuity in the better eye of bilaterally involved patients was 20/60 to 20/1000 (low vision according to the International Classification of Diseases, Ninth Revision, Clinical Modification) in 43.2% and less than 20/1000 (legally blind) in 24.3%. Fundus examination was performed in 82 eyes, and disorders were seen in 12 (12 of 82; 14.6%). Systemic abnormalities were present in 35 patients (35 of 139; 25.2%); a family history was present in 5 patients (5 of 139; 3.6%). Of the 160 eyes of 109 patients with Peters anomaly, 51 patients (51 of 109; 46.8%) had bilateral Peters anomaly, 30 (30 of 109; 27.5%) had fellow eyes that were normal, and 28 (28 of 109, 25.7%) showed other abnormal ocular findings in the fellow eye. CONCLUSIONS: Anterior segment dysgenesis shows diverse clinical features, various severities of corneal opacities, and visual outcomes. Further understanding of the disease as an abnormality during embryogenesis and neural crest cell differentiations may be required.
Advances in Ophthalmology & Visual System · 2017 · 2 citations · open access
Update on Anterior Segment Development with Emphasis on Genetics and Correlation with Pathogenesis of Developmental & Primary Open Angle Glaucoma
AbstractThe ocular anterior segment structures are derived from periocular mesenchyme, which consists of neural crest cells and cranial paraxial mesoderm. Many embryological facts have been developed based on the fates of neural crest and mesoderm in mice and in chick. The interactions between the ocular mesenchyme and the surface ectoderm derived cells are also essential for the coordination of anterior segment development. These interactions are mediated by several transcription factors expressed in both the epithelial and mesenchymal cells and are being extensively studied. Anterior Segment dysgenesis (ASD) is a spectrum of disorders of variable phenotypic expressions caused by abnormal migration and differentiation of neural crest cells. Patients with ASD are susceptible to develop infantile glaucoma, congenital endothelial dystrophy, sclerocornea and aniridia. There has been an evident overlapping observation in the genetic mutations between the ASD phenotypic spectrum and glaucoma especially the primary congenital glaucoma (PCG) since it involves abnormal development of Schlemm's canal and the drainage structures. In this review, we are highlighting the steps in the embryological development of the anterior segment chamber structures. We also present the role of various transcription factors and link the above information to some of the genetic abnormalities, which are known in association with the pathogenesis of glaucoma.
Relationship Between Neural Crest Cell Specification and Anterior Segment Dysgenesis
AbstractDevelopment of the anterior segment of the eye is closely associated with neural crest cell migration and specification. Its development is complex as it requires the functioning of a combination of local factors, receptors, inductors, and signalling between tissues such as the optic cup and periocular mesenchyme (POM). POM is comprised of neural crest-derived mesenchymal progenitor cells that give rise to numerous important anterior segment structures such as the cornea, and trabecular meshwork. Several genes involved in the migration and specification of the POM have been identified, including PITX2, FOXC1, and Tfap2b. The author, with the help of Judith West-Mays and Vanessa Martino, has conducted an extensive literature search on recently published articles surrounding anterior segment dysgenesis and its associated genes and transcription factors in order to construct this review paper.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
